Nutrition-First Framework Supports GLP-1 and Dual Incretin Therapy for Obesity, Mitigating Side Effects and Enhancing Maintenance

While glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists have revolutionized obesity treatment, their real-world effectiveness is often hampered by gastrointestinal adverse events, reduced dietary intake, disproportionate fat-free mass loss, and subsequent weight regain. Current pharmacotherapy alone often overlooks critical nutritional support, leading to suboptimal patient outcomes and adherence. A significant gap exists in integrating structured nutritional guidance directly into these powerful pharmacological pathways, which is crucial for maximizing benefits and minimizing common drawbacks.

This narrative review synthesized current evidence across five key domains: pharmacological mechanisms of incretin therapies, nutritional science, gastrointestinal physiology, body composition, and implementation science. The authors aimed to propose an evidence-informed, practical nutrition-first framework for patients undergoing GLP-1RA or dual incretin therapy for obesity. Given the limited direct trials on structured nutrition interventions specifically within GLP-1RA- or dual incretin-treated populations, many recommendations were extrapolated from the broader literature on obesity, caloric restriction, body composition, gastrointestinal management, and expert consensus guidelines.

The review translates the pharmacologic mechanisms of incretin therapies into practical dietary strategies designed to optimize patient outcomes. Key components of the proposed framework include protein prioritization to mitigate fat-free mass loss, implementation of structured meal patterns to manage satiety and intake, and comprehensive hydration and fiber management to alleviate common gastrointestinal symptoms. Symptom-targeted interventions are also outlined to address specific adverse events. Furthermore, the framework emphasizes resistance-training support to preserve muscle mass and robust maintenance planning to prevent weight regain post-therapy. These integrated strategies aim to address meal-related symptom burden, ensure adequate protein and fluid intake, identify patients at higher nutritional or body-composition risk, and prepare individuals for sustainable, long-term weight-management behaviors.

Integrating structured nutrition care into pharmacotherapy pathways may help translate pharmacologic efficacy into durable, patient-centered outcomes by addressing symptom burden and supporting long-term behavioral changes.